TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04783493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive magnetic stimulation of the spinal cord
Description: Non-invasive transcutaneous magnetic stimulation of the dorsal spine will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (chest level T2-T3). The stimulation intensity will represent 100% of the motor threshold. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hz repeated at 5 Hz. In total, 1200 pulses will be applied for 3 minutes and 58 seconds
Study: NCT05822401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR)
Description: Blood flow restricted training integrated into the daily work tasks for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care (control)
Description: Will continue their work as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (control)
Description: Will continue their work as usual
Study: NCT04783493

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coil will not be connected to the stimulation device
Description: coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, far from its field of view, to provide idea from the sound stimulus that is being stimulated
Study: NCT04908566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody combined with FOLFIRINOX regimen
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: irinotecan 150mg/m2, d1; fluorouracil 2400 mg/m², d1-2, continuous pumping for 46 hours; leucovorin 200 mg/m², d1; oxaliplatin 65 mg/m², d1; PD-1 antibody repeats once every 3 weeks; Chemotherapy is repeated every 2 weeks. 4 cycles before surgery. 4 cycles after operation。

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 antibody combined with SOX program
Description: Give 240 mg of PD-1 antibody before each cycle of chemotherapy, d1; Chemotherapy regimen: oxaliplatin 130 mg/m², d1, ticgio 40-60mg bid, d1-14 q3w;Repeat once every 3 weeks.~2-4 cycles before surgery. The perioperative period was 8 cycles.
Study: NCT05458609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant 10 mg
Description: 10 mg of Lemborexant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: 50 mg of Naltrexone
Study: NCT04874246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: During robot-assisted laparoscopic myomectomy, vasopressin diluted to different concentrations will be injected before uterine serosal incision.
Study: NCT06001632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: krill oil (SuperbaBoostTM)
Description: 4 g/day of Krill oil supplements (LC n-3 PUFAs) (1g capsule containing 191mg EPA, 94mg DHA and 78mg choline).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4g/day of mixed vegetable oil
Description: vegetable oil capsules (mixture of olive oil (extra virgin, cold-pressed), maize oil (refined), palm kernel oil (refined) and medium-chain triglycerides, in the ratio 4:4:3:2).
Study: NCT05228522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: 16-week family-focused intervention that includes nutrition education, behavioral change skills training, and physical activity.
Study: NCT05221580

Intervention type: DRUG
Intervention: Ryzodeg®
Description: Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Study: NCT04784000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1: AT-527 550 mg
Description: AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1: AT-527 550 mg
Description: AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: carbamazepine
Description: Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: carbamazepine
Description: Carbamazepine 100 mg twice daily (BID) Days 3 to 6, 200 mg BID on Days 9 to 11, 300 mg BID on Days 12 to 25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3: AT-527 550 mg + carbamazepine
Description: AT-527 550 mg tablet (1 x 550 mg tablet, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3: AT-527 1100 mg + carbamazepine
Description: AT-527 1100 mg tablet (2 x 550 mg tablets, in the morning) on Day 26 plus carbamazepine 300 mg BID on Day 26
Study: NCT05143671

Intervention type: PROCEDURE
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting in coronary revascularization.

Intervention type: PROCEDURE
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting in coronary revascularization.

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention in coronary revascularization.

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention in coronary revascularization.

Intervention type: PROCEDURE
Intervention: Surgical valve replacement
Description: Surgical mitral and / or aortic valve replacement.

Intervention type: PROCEDURE
Intervention: Carotid artery stenting
Description: Carotid artery stenting.
Study: NCT06121453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Adherence Intervention
Description: multi-part intervention to reduce barriers to medication use
Study: NCT05178407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cube
Description: Bouillon cube fortified with 80 µg/g folic acid, 1.2 µg/g Vitamin B12, 3 mg/g Zinc (ZnO), 4 mg/g Iron (FePP/citric acid/trisodium citrate), 200 µg/g Vitamin A (retinyl palmitate), 30 µg/g Iodine (KIO3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control bouillon cube (iodine-only)
Description: Bouillon cube fortified with 30 µg/g Iodine (KIO3)
Study: NCT06130735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Computerized Training
Description: Participants will log into ABI Wellness Platform five days per week (M-T-W-Th-F) and train using the Symbol Relations module for 45 to 60 minutes. Every other week, participants will meet with their training facilitator via zoom to review training progress and troubleshoot any training-related questions.
Study: NCT04637438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: FMT via colonoscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water infusion via colonoscopy
Study: NCT05052138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tactile massage
Description: Tactile massage will receive two 15-min tactile massages(hand massage) per week for 4weeks
Study: NCT06291688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile healthcare education game
Description: Game group will download an APP on a smart phone and play the mobile game which contains the educaitonal content regarding EGFR-related cutaneous adverse drug reactions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile healthcare education application
Description: Text group will download an APP on a smart phone and open the APP to see the text regarding EGFR-related cutaneous adverse drug reactions.
Study: NCT04790084

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05478148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gingival thickness
Description: After the classification the phenotype, gingival thickness was measured with Endodontic File and Modified Florida Probe from the 3 different points. First point was the probing depth level, second one was 1mm apical to this level and third one from the 2mm apical to probing depth.
Study: NCT05898204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Prescription of a ketogenic diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced diet
Description: Prescription of a balanced diet, 1200 Kcal/die. Patients are encouraged to walk 30 minutes every day.
Study: NCT06539910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS block
Description: Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection. Distal adductor canal block via another needle puncture.Ten mL of a mixture of 0.25 % bupivacaine and 8 mg dexamethasone will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane lateral to medial approach just lateral to the superficial femoral artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified TIPS block
Description: Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane.Both groups will receive a mixture of 0.25 % bupivacaine and 8 mg dexamethasone. Ten mL will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA anaesthetic mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane medial to lateral approach just lateral to the superficial femoral artery. Then, the needle will be redirected just underneath the ALM and 10 mL of the LA mixture will be injected in the plane between the ALM and the adductor magnus muscle (AMM).Total volume of LA will be 50 mL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutimodal analgesia
Description: Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mutimodal analgesia
Description: Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes
Study: NCT05404620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth exercises
Description: 9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF technique
Description: 9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
Study: NCT05357157

Intervention type: OTHER
Intervention: Electroacupuncture
Description: Subjects will be administered electroacupuncture as described in the electroacupuncture group description

Intervention type: OTHER
Intervention: Electroacupuncture
Description: Subjects will be administered electroacupuncture as described in the electroacupuncture group description

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrition
Description: Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary supplement
Description: Subjects will be administered the intervention described in the electroacupuncture nutrition and dietary supplement group description
Study: NCT06440655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Subjects were treated by Platelet rich plasma in each side of head (Left or right)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Subjects were treated by Platelet rich fibrin in each side of head (Left or right)
Study: NCT05975970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoTrain AR
Description: MyoTrain AR is a virtual prosthesis functional training system. From a hardware perspective it consists of an augmented reality head-mounted display (HMD), four SteamVR kinematic trackers, eight surface EMG electrodes based on the Element electrode platform, and a desktop computer to facilitate wireless communication between the various hardware components. From a software perspective, MyoTrain AR was developed in the cross-platform Unity 4.0 game development engine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery
Description: Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
Study: NCT05549856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet suction
Description: The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). Before puncturing the lesion, flush the needle with 5ml saline, then use a 10 ml syringe in order to replacing the column of air with fluid. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry suction
Description: The pancreatic solid lesions will be puncture with the 22G Acquire needle (Boston Scientific Corporation, Marlborough, MA, USA). The stylet is removed and a 10 ml air-filled pre-vacuum syringe is attached. After puncture, monitoring the puncture needle under US guidance in real time, the needle was moved back and forth about 10-20 times within the lesion using a fanning technique.
Study: NCT05710978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Work Protocol
Description: Participants will complete 4 hours of walking and cycling to a work:rest ratio of 3:1.
Study: NCT06145815

Intervention type: PROCEDURE
Intervention: Arthroscopic rotator cuff repair
Description: Patients underwent an arthroscopic repair for rotator cuff lesions

Intervention type: PROCEDURE
Intervention: Arthroscopic rotator cuff repair
Description: Patients underwent an arthroscopic repair for rotator cuff lesions
Study: NCT06224725

Intervention type: OTHER
Intervention: dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)
Description: Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.

Intervention type: OTHER
Intervention: dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)
Description: Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
Study: NCT05188937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: validity and reliability study
Description: Validity and reliability assessment of the Dual-task Questionnaire
Study: NCT04997694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre Heating
Description: Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre Heating
Description: Before anesthesia was given, the participants were warmed for 20 minutes with prewarming techniques. Presence of postoperative hypothermia, vital signs and temperature comfort level were evaluated.
Study: NCT05326542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESWL and ERCP
Description: First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LL and ERCP
Description: After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.
Study: NCT05035615

Intervention type: DIAGNOSTIC_TEST
Intervention: IUO Acute Leukemia Panel
Description: This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
Study: NCT04221932

Intervention type: DEVICE
Intervention: CRRT KPI Reports
Description: This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).

Intervention type: DEVICE
Intervention: CRRT KPI Reports
Description: This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
Study: NCT06368713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: * Frequency: Exercise sessions will occur no less than three times per week.~* Intensity: The intensity will be based on a rating of perceived exertion score ranging from 12 to 16 on a scale of 6 to 20.~* Exercise duration: Each exercise session will last approximately 30 minutes.~* Exercise Type:The exercise regimen will include aerobic exercise, resistance exercise, and flexibility training.
Study: NCT05413486

Intervention type: OTHER
Intervention: Observational
Description: Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.

Intervention type: OTHER
Intervention: Observational
Description: Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.

Intervention type: OTHER
Intervention: Observational
Description: Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.

Intervention type: OTHER
Intervention: Observational
Description: Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups.
Study: NCT05559190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field
Description: Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graduated abdominal strengthening exercises
Description: Four specific muscle core exercises were performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graduated abdominal strengthening exercises
Description: Four specific muscle core exercises were performed
Study: NCT04867473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teleyoga
Description: 12 weekly 75 minute therapist-led teleyoga sessions